However, work by Huffman et al. and Romero et al., highlighting its role in promoting anti-tumor CD4+ responses in response to CD40 agonists and an inflammatory, effector T-cell phenotype in PDAC, respectively, demonstrates how CCL5’s role is possibly context-dependent [34,123]. The gene discussed is CD4; the disease is neoplasm.